Incyte (INCY) Set to Announce Earnings on Tuesday

Incyte (NASDAQ:INCY - Get Free Report) will announce its earnings results before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of $1.10 per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts' consensus estimates of $0.78 by ($2.60). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.01 billion. Incyte had a net margin of 2.52% and a return on equity of 0.75%. The firm's revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.77 EPS. On average, analysts expect Incyte to post $1 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Trading Up 0.5 %

Shares of NASDAQ INCY traded up $0.32 during midday trading on Tuesday, reaching $65.59. 734,953 shares of the stock were exchanged, compared to its average volume of 2,343,539. The company has a 50 day simple moving average of $64.94 and a 200 day simple moving average of $61.08. The stock has a market capitalization of $14.73 billion, a P/E ratio of 19.88, a PEG ratio of 5.30 and a beta of 0.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.84 and a current ratio of 1.92. Incyte has a twelve month low of $50.27 and a twelve month high of $70.36.

Analyst Upgrades and Downgrades

INCY has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Incyte from $59.00 to $61.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 31st. Bank of America increased their price objective on shares of Incyte from $66.00 to $68.00 and gave the stock a "neutral" rating in a research report on Monday, September 16th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Incyte in a research report on Monday, September 16th. William Blair reaffirmed an "outperform" rating on shares of Incyte in a research report on Monday, September 9th. Finally, Wells Fargo & Company decreased their price target on shares of Incyte from $63.00 to $62.00 and set an "equal weight" rating for the company in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $73.21.

Insider Buying and Selling at Incyte

In other Incyte news, insider Thomas Tray sold 572 shares of Incyte stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the transaction, the insider now directly owns 24,825 shares in the company, valued at approximately $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Thomas Tray sold 572 shares of Incyte stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the sale, the insider now owns 24,825 shares of the company's stock, valued at $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vijay K. Iyengar sold 15,571 shares of Incyte stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the completion of the sale, the executive vice president now directly owns 36,701 shares in the company, valued at approximately $2,569,070. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,593 shares of company stock worth $1,652,914. 17.50% of the stock is owned by company insiders.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.